Monoclonal antibodies are also involved in migraine therapy
The research focused on the pathophysiology of migraine lead to the discovery of the key role that anti-calcitonin gene-related peptide (CGRP) play in its etiopathogenesis and to the development of new drugs. Anti-CGRP mabs are highly effective for the prevention of migraine and represent a promising new solution for patients and their physicians. eptinezumab from Lundbeck; erenumab from Amgen; fremanezumab from Teva Pharmaceuticals and galcanezumab from Eli Lilly and Company are among these […]